ATOS — Atossa Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
Brief: Atossa Therapeutics Files For Mixed Shelf Of Up To $100 Mln
Brief: Atossa Therapeutics Announces Support Of New Breast Cancer Screening Guidelines
Brief: Atossa Therapeutics Announces Expanded Research Agreement With Weill Cornell To Evaluate Synergy Between ADCS And Endoxifen
French and Benelux stocks-Factors to watch (updated)
Media: Atos CEO says debt talks will save company in a plan to be finalized by July - Bloomberg News
Brief: Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial
Atossa Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Aspen Aerogels, Daseke, Karuna Therapeutics
Brief: Atossa Therapeutics Names Arezoo Mirad As Senior Medical Director
Brief: Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
Atossa Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Atossa Therapeutics - On October 2, Greg Weaver Provided Notice Of His Resignation As Executive Vice President And CFO
Brief: Atossa Therapeutics Got Letter From Nasdaq Notifying That Co Was Not In Compliance With Nasdaq Listing Rule
U.S. RESEARCH ROUNDUP- Autozone, Sherwin-Williams, Walmart
Brief: Atossa Therapeutics - On August 30, Intas Pharmaceuticals Ltd Filed A Petition For Post Grant Review With U.S. Patent And Trademark Office
Atossa Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview